Hypolipidemic treatment of heterozygous familial hypercholesterolemia: A lifelong challenge

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 3, 2004, Pages 405-415

  Vuorio, Alpo F ^a   Kovanen, Petri T ^b   Gylling, Helena ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b WIHURI RESEARCH INSTITUTE   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Atherosclerosis; Combination therapy; Ezetimibe; Familial hypercholesterolemia; hsCRP; LDL cholesterol; LDL receptor; Stanol; Statin; Treatment

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MARGARINE; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; PREVALITE; ROSUVASTATIN; SIMVASTATIN; STANOL ESTER; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZEITA;

ADULT; ARTERY INTIMA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEPRESSION; DIET THERAPY; DRUG MEGADOSE; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; INTERNAL CAROTID ARTERY; PHENOTYPE; REVIEW; SCHOOL CHILD; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MUTATION; RECEPTORS, LDL;

EID: 2542457600     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.3.405     Document Type: Review

References (110)

1. Tonstad S, Joakimsen O, Stenlands-Bugge E et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler. Thromb. Vasc. Biol. 16(8), 984-991 (1996).
2. Hoffmann U, Dirisamer A, Heher S, Kostner K, Widhalm K, Neunteufl T. Relation of flow-mediated vasodilatation and coronary arterial calcium in young patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 90(1), 70-73 (2002).
3. Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation 79(2), 225-232 (1989).
4. Buja LM, Kovanen PT, Bilheimer DW. Cellular pathology of homozygous familial hypercholesterolemia. Am. J. Pathol. 97(2), 327-357 (1979).
5. Napoli V, D'Armiento FP, Mancini FP et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of LDL and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J. Clin. Invest. 100(11), 2680-2690 (1997).
6. Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: fate of early lesions in children (FELIC) study. Lancet 354(9186), 1234-1241 (1999).
7. Brown MS, Kovanen PT, Goldstein JL et al. Prenatal diagnosis of homozygous familial hypercholesterolemia. Expression of a genetic receptor disease in utero. Lancet 1(8063), 526-529 (1978).
8. Lin DS, Pitkin RM, Connor WE. Placental transfer of cholesterol into the human fetus. Am. J. Obstet. Gynecol. 128(7), 735-739 (1977).
9. Vuorio AF, Miettinen TA, Turtola H, Oksanen H, Gylling H. Cholesterol metabolism in normal and heterozygous familial hypercholesterolemic newborns. J. Lab. Clin. Med. 140(1), 35-42 (2002).
10. Glueck CJ, Christopher C, Tsang RC, Mellies MJ. Cholesterol-free diet and the physiologic hyperlipidemia of pregnancy in familial hypercholesterolemia. Metabolism 29(10), 949-955 (1980).
11. Vuorio AF, Aalto-Setälä K, Koivisto U-M et al. Familial hypercholesterolaemia in Finland: common, rare and mild mutations of the LDL-receptor and their clinical consequences. Ann. Med. 33(6), 410-421 (2001).
12. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart J. 24(17), 1601-1610 (2003).
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143-3412 (2002).
14. The American Society of Human Genetics Board of Directors and The American Genetics Board of Directors. Points to consider: ethical, legal and psychosocial implications of genetic testing in children and adolescents. Am. J. Hum. Genet. 57(5), 1233-1241 (1995).
15. Wertz DC, Reilly PR. Laboratory policies and practices for the genetic testing of children: a survey of the Helix Network. Am. J. Hum. Genet. 61(5), 1163-1168 (1997).
16. Williams CL, Hayman LL, Daniels SR et al. Cardiovascular health in childhood. A statement of health professionals from the committee on Atherosclerosis, Hypertension and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 106(1), 143-160 (2002).
17. Hayden MR, Josephson R. Development of a program for identification of patients with familial hypercholesterolemia in British Columbia: a model for prevention of coronary heart disease. Am. J. Cardiol. 72(10), 25D-29D (1993).
18. Kotze MJ, Langehoven E, Theart L, Theart L, Marx MP, Oosthuizen CJ. Report on a molecular diagnostic service for familial hypercholesterolemia in Afrikaners. Gen. Couns. 5(1), 15-21 (1994).
19. Baron H, Fung S, Aydin A, Bahring S, Luft FC, Schuster H. Oligonucleotide ligation assay (OLA) for the diagnosis of familial hypercholesterolemia. Nat. Biotech. 14(10), 1279-1282 (1996).
20. Vuorio AF, Turtola H, Piilahti KM, Repo P, Kanninen T, Kontula K. Familial hypercholesterolemia in the Finnish North Karelia: a molecular, clinical and genealogical study. Arterioscler. Thromb. Vasc. Biol. 17(11), 3127-3138 (1997).
21. Vuorio AF, Turtola H, Kontula K. Neonatal diagnosis of familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 17(11), 3332-3337 (1997).
22. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: The Metabolic Bases of Inherited Dieases 7th ed. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds). McGraw-Hill Book Co, NY, USA 1981-2030 (1995).
23. Miserez AR, Keller U. Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 15 (10), 1719-1729 (1995).
24. Lapinleimu H, Viikari J, Jokinen E et al. Prospective randomized trail in 1062 infants of a diet low in saturated fat and cholesterol. Lancet 345(8948), 471-476 (1995).
25. Niinikoski H, Viikari J, Ronnemaa T et al. Prospective randomized trial of low-saturated-fat, low-cholesterol diet during the first 3 years of life. Circulation 94(6), 1386-1393(1996)
26. Poustie VJ, Rutherford P. Dietary treatment for familial hypercholesterolemia (Cochrane Review). In: The Cochrane Library, Issue 4. John Wiley & Sons Ltd, Chichester, UK (2003).
27. Lichtenstein AH, Deckelbaum RJ for the American Heart Association Nutrition Committee. Stanol/sterol ester-containing foods and blood cholesterol levels. Circulation 103(8), 1177-1179 (2001).
28. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N. Engl. J. Med. 333(20), 1308-1312 (1995).
29. Gylling H, Siimes MA, Miettinen TA. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. J. Lipid Res. 36(8), 1807-1812 (1995).
30. Vuorio AF, Gylling H, Turtola H, Kontula K, Ketonen P, Miettinen TA. Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation. Arterioscler. Thromb. Vasc. Biol. 20(2), 500-506 (2000).
31. Amundsen ÅL, Ose L, Nenseter M, Ntanios FY. Plant sterol ester-enriched spread lowers plasma total and LDL-CHOLESTEROL in children with familial hypercholesterolemia. Am. J. Clin. Nutr. 76(2), 338-344 (2002).
32. Katan MB, Grundy SM, Jones P, Law M. Miettinen TA, Paoletti R for the Stresa Workshop Participants. Efficacy and safety of plant stanols and sterols in management of blood cholesterol levels. Mayo Clin. Proc. 78(8), 965-978 (2003).
33. Glueck CJ, Tsang RC, Fallat RW, Mellies M. Therapy of familial hypercholesterolemia in childhood: diet and cholestyramine resin for 24 to 36 months. Pediatrics 59(3), 433-441 (1977).
34. Glueck CJ, Mellies M, Dine M, Perry T, Laskarzewski P. Safety and efficacy of long-term diet and diet plus bile acid-binding resin cholesterol-lowering therapy in 73 children heterozygous for familial hypercholesterolemia. Pediatrics 78(2), 338-348 (1986).
35. West RJ, Lloyd JK, Leonard JV. Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine. Lancet 2(8200), 873-875 (1980).
36. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J. Pediatr. 129(1), 42-49 (1996).
37. Tonstad S, Sivertsen M, Aksnes L, Ose L. Low dose colestipol in adolescents with familial hypercholesterolaemia. Arch. Dis. Child. 74(2), 157-160 (1996).
38. Schlierf G, Mrozik K, Heuck CC et al. 'Low dose' colestipol in children, adolescents and young adults with familial hypercholesterolaemia. Atherosclerosis 41(1), 133-138 (1982).
39. Stein E, Kreisberg R, Miller V, Mantell G, Washington L, Shapiro DR. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Arch. Intern. Med. 150(2), 341-345 (1990).
40. Betteridge DJ, Bhatnager D, Bing RF et al. Treatment of familial hypercholesterolemia: United Kingdom lipid clinics study of pravastatin and cholestyramine. Br. Med. J. 304(6838), 1335-1338 (1992).
41. West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut 16(2), 93-98 (1975).
42. Knipscheer HC, Boelen CC, Kastelein JJ et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr. Res. 39(5), 867-871 (1996).
43. Lambert M, Lupien P-J, Gagné C et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Pediatrics 97(5), 619-628 (1996).
44. Stein EA, Illingworth DR, Kwiterovich PO Jr et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 281(2), 137-144 (1999).
45. de Jongh S, Ose L, Szamosi T et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. A randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 106(17), 2231-2237 (2002).
46. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in childen and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J. Pediatr. 143(1), 74-80 (2003).
47. McCrindle BW, Helden E, Cullen-Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr. Res. 51(6), 715-721 (2002).
48. Couture P, Brun LD, Szots F et al. Association of specific LDL-receptor gene mutations with differential plasma lipoprotein responses to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler. Tromb. Vasc. Biol. 18(6), 1007-1012 (1998).
49. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJP. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J. Am. Coll. Cardiol. 40(12), 2117-2121 (2002).
50. Tonstad S, Novik TS, Vandvik IH. Psychosocial function during treatment for familial hypercholesterolemia. Pediatrics. 98(2),249-255 (1996).
51. Goldstein JL, Helgeson JA, Brown MS. Inhibition of cholesterol synthesis with compactin renders growth of cultured cells dependent on the low density lipoprotein receptor. J. Biol. Chem. 254(12), 5403-5409 (1979).
52. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 343(6257), 425-430 (1990).
53. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934), 1383-1389 (1994).
54. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333(20), 1301-1307 (1995).
55. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. Med. 335(14), 1001-1009 (1996).
56. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 279(20), 1615-1622 (1998).
57. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Stud Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339(19),1349-1357 (1998).
58. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomised placebo-controlled trial. Lancet 360(9326), 7-22 (2002).
59. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis. Br. Med. J. 326(7404), 1423-1429(2003).
60. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 142(1), 105-112 (1999).
61. Smilde TJ, van Wissen S, Wollerscheim H, Trip MD, Kastelein JPP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357(9256), 577-581 (2001).
62. de Sauvage Nolting PR, de Groot E, Zwinderman AH et al. Regression of carotid femoral intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. Arch. Int. Med. 163(15), 1837-1841 (2003).
63. Kajinami K, Koizumi J, Ueda K et al. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hyperholesterolemia. Am. J. Cardiol. 85(2), 178-183 (2000).
64. Noji Y, Higashikata T, Inazu A et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 163(1), 157-164 (2002).
65. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am. J. Cardiol. 88(5), 504-508 (2001).
66. Davidson M, Ma P, Stein E et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with Type IIa or IIb hypercholesterolemia. Am. J. Cardiol. 89(3), 268-275 (2002).
67. Leitersdorf E, Eisenberg S, Eliav O et al. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 87(4 Suppl. III), 35-44 (1993).
68. Jeenah M, September W, Graadt van Roggen F et al. Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin in familial hypercholesterolemia. Atherosclerosis 98(1), 51-58 (1993).
69. Kajinami K, Yagi K, Higashikata T, Inazu A, Koizumi J, Mabuchi H. Low-density lipoprotein receptor genotype dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. Am. J. Cardiol. 82(1), 113-117 (1998).
70. Heath KE, Gudnason V, Humphries SE, Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 143(1), 41-54 (1999).
71. Leren TP, Hjermann I. Is responsiveness to lovastatin in familial hypercholeterolemia heterozygotes influenced by the specific mutation in the low-density lipoprotein receptor gene? Eur. J. Clin. Invest. 25(12), 967-973 (1995).
72. Vuorio AF, Ojala JP, Sarna S, Turtola H, Tikkanen MJ, Kontula K. Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment. J. Intern. Med. 237(1), 43-48 (1995).
73. Sun XM, Patel DD, Knight BL, Soutar AK, The Familial Hypercholesterolemia Regression Study Group. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study Group. Atherosclerosis 136(1), 175-185 (1998).
74. Sijbrands EJ, Lombardi MP, Westendorp RG et al. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations. Atherosclerosis 136(2), 247-254 (1998).
75. Brorholt-Petersen JU, Jensen HK, Raungaard B, Gregersen N, Faergeman O. LDL-receptor gene mutations and the hypercholesterolemic response to statin therapy. Clin. Genet. 59(6), 397-405 (2001).
76. O'Neill FH, Patel DD, Knight BL et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 21(5), 832-837 (2001).
77. Miettinen TA, Gylling H, Strandberg T, Sarna S. Baseline serum cholestanol as a predictor of recurrent coronary events in subgroup of Scandinavian Survival Study. Br. Med. J. 316(7138), 1127-1129 (1998).
78. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet. 353(9147), 118-119 (1999).
79. Albert MA, Danielson E, Rifai N, Ridker PM, for the PRINCE Investigators. Effect of statin therapy of C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286(1), 64-70 (2001).
80. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100(3), 230-235 (1999).
81. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 107(3), 499-511 (2003).
82. Pearson TA. New tools for coronary risk assessment? What are their advantages and limitations? Circulation 105(7), 886-892 (2002).
83. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease. A critical review of the evidence. JAMA 290(7), 932-940 (2003).
84. Mohrschladt MF, de Maat MPM, Westendorp RGJ, Smelt AHM. C-reactive protein in patients with familial hypercholesterolemia: no effect of simvastatin treatment. Atherosclerosis 157(2), 491-494 (2001).
85. van Wissen S, Trip MD, Smilde TJ, de Graaf J, Stalenhoef AF, Kastelein JJ. Differential hs-CRP reduction in patients with familial hypercholcsterolemia treated wit aggressive or coventional statin therapy. Atherosclerosis 165(2), 361-366 (2002).
86. van Haelst PL, van Doormal JJ, Asselbergs FW et al. Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholesterolaemia. Clin. Sci. 104(6), 627-632 (2003).
87. Kobayashi J, Katsube S, Shimoda M et al. Single LDL apheresis improves serum remnant-like particle-cholesterol, C-reactive protein and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects. Clin. Chim. Acta 321(1-2), 107-112 (2002).
88. Gotto Jr AM, Farmer JA. Pleiotropic effects of statins: do they matter? Curr. Opin. Lipidol. 12(4), 391-394 (2001).
89. Kontula K, Vuorio A, Turtola H, Saikku P. Association of seropositivity for Chlamydia pneumoniae and coronary artery disease in heterozygous familial hypercholesterolaemia. Lancet 354(9172), 46-47 (1999).
90. Hopkins PN, Stephenson S, Wu LL, Riley WA, Xin Y, Hunt SC. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 87(5), 547-553 (2001).
91. McKeone BJ, Patsch JR, Pownall HJ. Plasma triglycerides determine low density lipoprotein composition, physical properties and cell-specific binding in cultured cells. J. Clin. Invest. 91(5), 1926-1933 (1993).
92. Gaw A, Packard CJ, Murray EF et al. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler. Thromb. 13(2), 170-189 (1993).
93. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol. 20(1), 189-197 (2000).
94. Geiss HC, Schwandt P, Pashofer KG. Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and patients with diabetes mellitus mixed hyperlipoproteinemia. Exp. Clin. Endocrin. Diab. 110(4), 182-187 (2002).
95. Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 90(10), 1084-1091 (2002).
96. Uusitupa MI, Miettinen TA, Happonen P et al. Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum. Arterioscler. Thromb. 12(7), 807-813 (1992).
97. Miettinen TA, Strandberg TE, Gylling H. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients. Relation to basal serum cholestanol. Arterioscler. Thromb. Vasc. Biol. 20(5), 1340-1346 (2000).
98. Thompson GR, O'Neill F, Seed M. Why some patients respond poorly to statins and how this might be remedied. Eur. Heart J. 23(3), 200-206 (2002).
99. Gylling H, Miettinen TA. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J. Lipid. Res. 37(8), 1776-1785 (1996).
100. Gylling H, Radhakrishnan R, Miettinen TA. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol. Circulation 96(12), 4226-4231 (1997).
101. Blair SN, Capuzzi DM, Gottlieb SO et al. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am. J. Cardiol. 86(1), 46-52 (2000).
102. Miettinen TA. Cholesterol absorption inhibition: a strategy for cholesterol-lowering therapy. Int. J. Clin. Pract. 55(10), 710-716 (2001).
103. Davis Jr HR, Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler. Thromb. Vasc. Biol. 21(12), 2032-2038 (2001).
104. Davidson M, McQarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in 688 patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40(12), 2125-2134 (2002).
105. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107(19), 2409-2415 (2003).
106. Gagne C, Gaudet D, Bruckert E, Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105(21), 2439-2475 (2002).
107. White CW, Gobel FL, Campeau L et al. Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. Circulation 104(22), 2660-2665 (2001).
108. Gylling H, Miettinen TA. LDL-CHOLESTEROL lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterolemic subjects. Nutr. Metab. Cardiovasc. Dis. 12(1), 19-23 (2002).
109. Pasternak RC, Smith SC, Bairey-Merz CN et al. ACC/AHA/NHLBI Clinical Advisory on the use and safety of statins. Circulation 106(8), 1024-1028 (2002).
110. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 346(7), 539-540 (2002).